{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:59:40Z","timestamp":1770721180193,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Bipolar Disord"],"DOI":"10.1186\/s40345-026-00411-3","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:54:25Z","timestamp":1768402465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polycystic ovary syndrome in women with bipolar affective disorder or epilepsy exposed to valproic acid: a nationwide 16-year cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Maria","family":"Holmskov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie Frederiksen","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Eva","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 Ernst","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"8","key":"411_CR1","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1007\/S00415-024-12436-8","volume":"271","author":"H Angus-Leppan","year":"2024","unstructured":"Angus-Leppan H, Arkell R, Watkins L, Heaney D, Cooper P, Shankar R. New valproate regulations, informed choice and seizure risk. J Neurol. 2024;271(8):5671. https:\/\/doi.org\/10.1007\/S00415-024-12436-8.","journal-title":"J Neurol"},{"issue":"4","key":"411_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S10072-006-0675-Y","volume":"27","author":"L Bilo","year":"2006","unstructured":"Bilo L, Meo R. Epilepsy and polycystic ovary syndrome: where is the link? Neurol Sci. 2006;27(4):221\u201330. https:\/\/doi.org\/10.1007\/S10072-006-0675-Y.","journal-title":"Neurol Sci"},{"issue":"10","key":"411_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/09513590802288259","volume":"24","author":"L Bilo","year":"2008","unstructured":"Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol. 2008;24(10):562\u201370. https:\/\/doi.org\/10.1080\/09513590802288259.","journal-title":"Gynecol Endocrinol"},{"key":"411_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003196.PUB2","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD003196.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"key":"411_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110498","author":"W Dai","year":"2022","unstructured":"Dai W, Liu J, Qiu Y, Teng Z, Li S, Huang J, et al. Shared postulations between bipolar disorder and polycystic ovary syndrome pathologies. Prog Neuro-Psychopharmacol Biol Psychiatry. 2022. https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110498.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"4","key":"411_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/JHRS.JHRS_95_18","volume":"13","author":"R Deswal","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261. https:\/\/doi.org\/10.4103\/JHRS.JHRS_95_18.","journal-title":"J Hum Reprod Sci"},{"issue":"6","key":"411_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/ER.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981\u20131030. https:\/\/doi.org\/10.1210\/ER.2011-1034.","journal-title":"Endocr Rev"},{"issue":"1\u20132","key":"411_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eplepsyres.2011.07.006","volume":"97","author":"X Hu","year":"2011","unstructured":"Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97(1\u20132):73\u201382. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.07.006.","journal-title":"Epilepsy Res"},{"issue":"19","key":"411_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJM199311043291904","volume":"329","author":"J Isojarvi","year":"1993","unstructured":"Isojarvi J, Laatikainen TJ, Pakarinen AJ, Juntunen K, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329(19):1383\u20138. https:\/\/doi.org\/10.1056\/NEJM199311043291904.","journal-title":"N Engl J Med"},{"issue":"6","key":"411_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.mehy.2008.12.056","volume":"73","author":"B Jiang","year":"2009","unstructured":"Jiang B, Kenna HA, Rasgon NL. Genetic overlap between polycystic ovary syndrome and bipolar disorder: the endophenotype hypothesis. Med Hypotheses. 2009;73(6):996\u20131004. https:\/\/doi.org\/10.1016\/j.mehy.2008.12.056.","journal-title":"Med Hypotheses"},{"issue":"11","key":"411_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.biopsych.2005.10.017","volume":"59","author":"H Joffe","year":"2006","unstructured":"Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59(11):1078\u201386. https:\/\/doi.org\/10.1016\/j.biopsych.2005.10.017.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"411_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/OBR.12762","volume":"20","author":"SS Lim","year":"2019","unstructured":"Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339\u201352. https:\/\/doi.org\/10.1111\/OBR.12762.","journal-title":"Obes Rev"},{"issue":"10282","key":"411_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet (London England). 2021;397(10282):1375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00246-4.","journal-title":"Lancet (London England)"},{"issue":"7 Suppl","key":"411_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1403494810395825","volume":"39","author":"O Mors","year":"2011","unstructured":"Mors O, Perto GP, Mortensen PB. The danish psychiatric central research register. Scand J Public Health. 2011;39(7 Suppl):54\u20137. https:\/\/doi.org\/10.1177\/1403494810395825.","journal-title":"Scand J Public Health"},{"issue":"4","key":"411_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4088\/JCP.V63N0409","volume":"63","author":"C O\u2019Donovan","year":"2002","unstructured":"O\u2019Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry. 2002;63(4):322\u201330. https:\/\/doi.org\/10.4088\/JCP.V63N0409.","journal-title":"J Clin Psychiatry"},{"key":"411_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106968","author":"PA Ortiz Salas","year":"2022","unstructured":"Ortiz Salas PA, Rodr\u00edguez JH, Florez SJB, Suarez FE. Polycystic ovary syndrome and the new antiepileptic drugs: a systematic review. Epilepsy Res. 2022. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106968.","journal-title":"Epilepsy Res"},{"issue":"10","key":"411_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004.","journal-title":"CNS Drugs"},{"key":"411_CR18","doi-asserted-by":"publisher","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National prescription registry. Int J Epidemiol. 2016;dyw213. https:\/\/doi.org\/10.1093\/ije\/dyw213.","DOI":"10.1093\/ije\/dyw213"},{"issue":"16","key":"411_CR19","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/S00018-007-7079-X","volume":"64","author":"G Rosenberg","year":"2007","unstructured":"Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007;64(16):2090\u2013103. https:\/\/doi.org\/10.1007\/S00018-007-7079-X.","journal-title":"Cell Mol Life Sci"},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390. https:\/\/doi.org\/10.2147\/CLEP.S91125.","journal-title":"Clin Epidemiol"},{"key":"411_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/S42494-023-00125-4","author":"L Sha","year":"2023","unstructured":"Sha L, Wu Y, Lai W, Duan Y, Xia Y, Chen L. Heterogeneity in susceptibility to polycystic ovary syndrome among women with epilepsy. Acta Epileptol. 2023. https:\/\/doi.org\/10.1186\/S42494-023-00125-4.","journal-title":"Acta Epileptol"},{"issue":"10","key":"411_CR22","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/CLINEM\/DGAD463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447\u201369. https:\/\/doi.org\/10.1210\/CLINEM\/DGAD463.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"411_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15(2):210\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(15)00314-2.","journal-title":"Lancet Neurol"},{"key":"411_CR24","doi-asserted-by":"publisher","unstructured":"Verrotti A, D\u2019Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5). https:\/\/doi.org\/10.1111\/J.1467-789X.2010.00800.X.","DOI":"10.1111\/J.1467-789X.2010.00800.X"}],"container-title":["International Journal of Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40345-026-00411-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-026-00411-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-026-00411-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:07:58Z","timestamp":1770649678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40345-026-00411-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1186\/s40345-026-00411-3","relation":{},"ISSN":["2194-7511"],"issn-type":[{"value":"2194-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval or informed consent was required, as the study was conducted solely using anonymized, registry-based data in accordance with Danish data protection regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as the study is based exclusively on anonymized registry data without individual-level identifiable information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MH, ML and AC have no competing interests to disclose. JC received honoraria from serving on the Scientific Advisory Board of UCB Nordic and Eisai AB, honoraria from giving lectures from UCB Nordic and Eisai AB, and funding for a trip from UCB Nordic.REN has, within the past 3 years, been an investigator for Compass Pharmaceuticals and Boehringer-Ingelheim for clinical trials and has received speaking fees from Lundbeck, Teva Pharmaceuticals, Janssen-Cilag and Boehringer-Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}